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Abstract 
"New antibiotics with novel modes of action are required to combat the growing threat posed by multi-
drug resistant bacteria. Over the last decade, genome sequencing and other high-throughput techniques 
have provided tremendous insight into the molecular processes underlying cellular functions in a wide 
range of bacterial species. We can now use these data to assess the degree of conservation of certain 
aspects of bacterial physiology, to help choose the best cellular targets for development of new broad-
spectrum antibacterials. DNA replication is a conserved and essential process, and the large number of 
proteins that interact to replicate DNA in bacteria are distinct from those in eukaryotes and archaea; yet 
none of the antibiotics in current clinical use acts directly on the replication machinery. Bacterial DNA 
synthesis thus appears to be an underexploited drug target. However, before this system can be targeted 
for drug design, it is important to understand which parts are conserved and which are not, as this will 
have implications for the spectrum of activity of any new inhibitors against bacterial species, as well as 
the potential for development of drug resistance. In this review we assess similarities and differences in 
replication components and mechanisms across the bacteria, highlight current progress towards the 
discovery of novel replication inhibitors, and suggest those aspects of the replication machinery that have 
the greatest potential as drug targets." 
Keywords 
architecture, drug, underexploited, machinery, replication, dna, bacterial, conservation, target, CMMB 
Disciplines 
Life Sciences | Physical Sciences and Mathematics | Social and Behavioral Sciences 
Publication Details 
Robinson, A., Causer, R. J. & Dixon, N. E. (2012). Architecture and conservation of the bacterial DNA 
replication machinery, an underexploited drug target. Current Drug Targets, 13 (3), 352-372. 
This journal article is available at Research Online: https://ro.uow.edu.au/scipapers/2996 
352 Current Drug Targets, 2012, 13, 352-372  
 
 1389-4501/12 $58.00+.00 © 2012 Bentham Science Publishers 
Architecture and Conservation of the Bacterial DNA Replication 
Machinery, an Underexploited Drug Target 
Andrew Robinson, Rebecca J. Causer and Nicholas E. Dixon* 
School of Chemistry, University of Wollongong, Australia 
Abstract: New antibiotics with novel modes of action are required to combat the growing threat posed by multi-drug 
resistant bacteria. Over the last decade, genome sequencing and other high-throughput techniques have provided 
tremendous insight into the molecular processes underlying cellular functions in a wide range of bacterial species. We can 
now use these data to assess the degree of conservation of certain aspects of bacterial physiology, to help choose the best 
cellular targets for development of new broad-spectrum antibacterials.  
DNA replication is a conserved and essential process, and the large number of proteins that interact to replicate DNA in 
bacteria are distinct from those in eukaryotes and archaea; yet none of the antibiotics in current clinical use acts directly 
on the replication machinery. Bacterial DNA synthesis thus appears to be an underexploited drug target. However, before 
this system can be targeted for drug design, it is important to understand which parts are conserved and which are not, as 
this will have implications for the spectrum of activity of any new inhibitors against bacterial species, as well as the 
potential for development of drug resistance. In this review we assess similarities and differences in replication 
components and mechanisms across the bacteria, highlight current progress towards the discovery of novel replication 
inhibitors, and suggest those aspects of the replication machinery that have the greatest potential as drug targets.  
Keywords: DnaB, DnaC, DnaE, DNA polymerase IIIC, DnaG primase, helicase. 
INTRODUCTION 
 The overuse of antibiotics during the past 60 years has 
exerted strong selective pressure on pathogenic bacteria, dri-
ving many to develop effective mechanisms of drug resist-
ance [1]. Among the most notorious examples are methici-
llin-resistant strains of Staphylococcus aureus (MRSA) and 
vancomycin-resistant Enterococcus spp. (VRE), both Gram-
positives. An equal or perhaps greater threat, however, 
comes from Gram-negative bacteria like Acinetobacter and 
Pseudomonas spp., some strains of which are multi- or even 
pan-drug resistant [2-4]. Resistant bacteria have developed 
diverse strategies to evade antibiotic therapy and most 
worryingly, appear to be developing resistance against an 
ever-widening spectrum of antibiotic compounds [5]. There 
is thus an urgent need for the development of new antibiotics 
with entirely new modes of action to treat infections caused 
by these highly resistant bacteria [1, 2, 6-8]. Unfortunately, 
the development of novel antimicrobial compounds has all 
but ceased in recent years, in part because existing antibio-
tics were so effective prior to the widespread dissemination 
of drug resistant strains [2, 9]. Efforts to develop entirely 
novel antibiotics have been hampered by the inherent diffi-
culty of discovering appropriate cellular targets and func-
tional lead compounds. Most antibiotics developed in recent 
years have been simple modifications of older compounds, 
aimed primarily at circumventing problems with resistance 
[10].  
 The past decade has seen an explosion of data that 
greatly enhance our knowledge of bacterial physiology [11-  
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17]. High-throughput genome sequencing initiatives have 
generated more than 1000 complete bacterial genomes [18]. 
Many hundreds more are near completion. High-throughput 
gene knockout studies have been used to determine the 
essentiality of each individual gene in 14 different bacterial 
species [14]. For well-studied model organisms, such as 
Escherichia coli, large-scale attempts are being made to map 
the entire cellular protein-protein interaction network [19]. 
Structural genomics initiatives have now determined three-
dimensional structures for many hundreds of bacterial 
proteins [15]. In addition to these high-throughput studies, 
researchers using more traditional approaches have made 
many exciting discoveries in recent years. A highlight is the 
use of fluorescence microscopy to study the actions of 
individual proteins inside living bacterial cells, which has 
added clarity to support decades of in vitro studies [20]. 
Crucially, the data derived from genome sequencing and 
other high-throughput studies now allow us to extrapolate 
much of the information derived from traditional work with 
model organisms to other bacteria, including species that act 
as human pathogens [21].  
 Are there new opportunities for the discovery of novel 
antibiotic compounds buried within all these new data? Now 
is an ideal time to collate this information and use it to assess 
which among cellular processes might serve as useful targets 
for drug discovery studies. In general, the biological targets 
of antibiotics are: (i) essential for growth and propagation of 
bacterial cells, (ii) conserved across a wide range of human 
pathogens, and (iii) not present, or distinct from correspond-
ing processes, in humans. Promisingly, there remain some 
cellular systems in bacteria that satisfy these criteria, yet are 
not the targets of any current antibiotics. These systems 
might therefore include new targets for the rational design or 
discovery of novel antibiotic compounds. 
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 The replication of chromosomal DNA is one such pro-
cess. It is one of the most fundamental processes carried out 
by bacteria, yet currently only one functional class of anti-
biotics (the DNA gyrase inhibitors) targets DNA replication, 
and even then the mode of action is indirect [22]. The 
mechanisms underlying bacterial DNA replication are now 
well understood, particularly in E. coli [23-25]. DNA repli-
cation is carried out by a highly dynamic complex called the 
replisome, comprised of at least 13 different proteins (Table 
1). Complete replisome complexes from E. coli and Bacillus 
subtilis have been reconstituted from individually purified 
components and are fully functional in vitro [26, 27]. 
Minimal replicases have been assembled for other bacteria, 
namely the Gram-positive pathogens S. aureus [28] and 
Streptococcus pyogenes [29], the Gram-negative pathogen 
Pseudomonas aeruginosa [30] and the hyperthermophile 
Aquifex aeolicus [31]. Three-dimensional structures are now 
available for nearly all of the individual protein modules and 
even for some of the replisomal sub-complexes. The majo-
rity of protein-protein interactions have been mapped and are 
being studied in increasingly finer detail [32]. With an 
abundance of genome sequence data available, we can now 
extrapolate our understanding of E. coli DNA replication to 
other organisms [21].  
 Could new antibiotics be designed that target conserved 
aspects of the DNA replication machinery? If so, will it be 
possible to avoid the development of resistance encountered 
so often in the past? In this review we summarize current 
understanding of bacterial DNA replication, use genome 
sequence data to map the conservation of replication com-
ponents across the bacteria, summarize recent efforts to 
develop DNA replication inhibitors and identify unexploited 
components that are most likely to be useful as targets for 
drug discovery and rational drug design. 
BACTERIAL DNA REPLICATION 
 Although (often) functionally equivalent, the proteins 
that replicate chromosomal DNA in bacteria (Table 1) are 
distinct in sequence and structure from those in eukaryotes 
and archaea. Despite their enormous genetic diversity, all 
bacteria appear to share essentially the same mechanisms of 
chromosomal replication and most of the replication proteins 
are sufficiently conserved to be readily identified in trans-
lated genome sequences. Most bacteria contain a single cir-
cular chromosome, within which replication is initiated at a 
single site, the origin of replication, oriC [33]. The two 
strands of the template DNA are separated at the origin, 
yielding two fork structures. Replicative DNA polymerases 
(replicases) and accessory proteins are assembled onto each 
of these forks, and synthesize new DNA bidirectionally 
around the circular chromosome (Fig. 1A) until the two 
replication forks meet in the terminus region (Ter), located 
approximately opposite the origin. This eventually yields 
two copies of the bacterial chromosome, each containing one 
strand from the parental chromosome and one nascent 
strand. 
 The best-studied bacterial replication system is that of E. 
coli whose mechanism, for the most part, serves as a model 
for all bacteria. In E. coli, oriC is recognized first by the 
replication initiator protein DnaA, which exists in forms that 
contain tightly bound ATP or ADP. The origin contains a 
series of five 9-bp sequence repeats known as DnaA (or R) 
boxes, to which DnaA-ATP and DnaA-ADP bind, as well as 
three additional sites (I boxes) that are specific for the ATP-
bound form [34, 35]. DnaA appears to remain associated 
with boxes R1, R2 and R4 for most of the cell cycle. At the 
onset of a round of DNA replication, binding of ATP-bound 
DnaA molecules to the remaining sites (R3, I1, I2 and I3) 
leads to separation of the two template DNA strands at a 
nearby AT-rich region. Four separate systems regulate this 
process, ensuring that replication is initiated only once dur-
ing each cell cycle [34]. Following strand separation, one 
ring-shaped hexamer of the replicative helicase DnaB 
(DnaB6) is loaded onto each of the DNA strands in the same 
orientation and each proceeds to unwind the parental DNA 
duplex, creating replication forks that move away from the 
origin in opposite directions. The replicase, DNA poly-
merase III holoenzyme (Pol III HE), associates with the 
forks and synthesizes both new DNA strands, leaving two 
completed duplex structures in its wake. Like most DNA 
polymerases, Pol III cannot begin DNA synthesis on a 
single-stranded DNA template; it can only extend pre-
existing DNA or RNA primers. It is the DnaG primase that 
first associates with DnaB at the replication fork and 
constructs short RNA primers, which are then extended by 
Pol III to build each new DNA strand.  
 Following decades of contention, the stoichiometry of 
individual components within active replisomes has recently 
been measured in living E. coli cells [36]. While DnaG 
primase was not quantified in this study, existing structural 
and biochemical evidence indicate that three molecules are 
likely to be present at each fork [37-39]. Each replisome is 
comprised of two main sub-complexes: the primosome 
([DnaB6][DnaG]3), and Pol III HE ([]3[3’()][	2]3) 
(Fig 1B). The Pol III HE in turn contains three different 
subcomplexes: a single clamp loader complex (3’) 
tethers three core polymerases (), each of which when 
actively synthesizing DNA is associated with a dimeric 	-
sliding clamp. Three 	2 dimers are present at each replication 
fork [36]; the third could be associated with either the clamp 
loader or with the third  core. Each Pol III HE thus 
contains three polymerase cores that are tethered together 
through the clamp loader complex, and to their DNA subs-
trates by 	-sliding clamps. Each polymerase  subunit is 
accompanied by a proofreading  subunit, an exonuclease 
that removes errantly incorporated nucleotides at the 3’ end 
of the newly synthesized strand. DNA synthesis by Pol III 
core is carried out only in the 5’3’ direction; thus synthesis 
of one nascent strand (the leading strand) is continuous while 
synthesis of the other strand (the lagging strand) is discon-
tinuous. Synthesis on the lagging strand occurs in four 
stages. Firstly DnaG primase associates with the DnaB 
helicase (which translocates on the lagging strand), recog-
nizes a trinucleotide recognition sequence and produces an 
RNA primer (of up to 14 nt). This happens about once every 
1000 nt during lagging strand synthesis. A 	-sliding clamp is 
loaded at the newly primed site by the clamp loader 
complex, onto which a Pol III core then associates. The Pol 
III core synthesizes new DNA until it reaches the preceding 
primer, producing an ~1 kb Okazaki fragment. The Pol III 
core is then transferred onto a subsequent (upstream) 	- 
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Table 1. Bacterial DNA Replication Proteins 
 
Protein Function 
Phylogenetic 
distribution 
Essentiality* 
Enzymatic 
activity
†
 
Interaction partners Structures
‡
 (organism)*
 
References 
Initiation complex       
DnaA initiator all bacteria 
Ab, Bs, Ec, Fn, Hi, 
Mg, Mp, Mt, Pa, 
Sa 
ATPase DnaB, Hda, DiaA, Dps, 
HU, DNA 
2HCB (Aa), 1L8Q (Aa), 2E0G 
(Ec), 2Z4R (Tm) 
[161, 170-176] 
Hda initiation 
suppressor 
/ 	/
-
proteobacteria 
Ec, Pa ATPase 	, DnaA 3BOS (Sh) [162, 177] 
YabA initiation 
suppressor 
firmicutes D  	, DnaA – [178] 
DnaB helicase co-
loader 
firmicutes, 
tenericutes 
Bs, Sa  DnaC (helicase), DnaD, 
DnaI 
– [55, 179] 
DnaC helicase 
loader 
enterobacteria, 
Aquificae 
Ec, St ATPase DnaB (helicase), DNA 3ECC (Aa) [49, 53, 54] 
DnaD DNA 
remodelling 
firmicutes Bs, Sa, Sn  DnaB, DnaI 2V79 (Bs) [55, 63, 180] 
DnaI helicase 
loader 
firmicutes Bs, Sa, Sn ATPase DnaC (helicase), DnaB, 
DnaD, DNA 
2K7R (Bs), 2W58 (Gk) [58, 181] 
Primosome       
DnaB/DnaC DNA helicase all bacteria 
Ab, Bs, Ec, Fn, Hi, 
Mg, Mp, Mt, Pa, 
Sa, Sn 
ATPase DnaA, DnaC/DnaI, 
DnaG, , Rep, DNA 
2Q6T (Ta), 2VYE (Gk), 2R6A 
(Gs), 1B79 (Ec), 1JWE (Ec), 
2R5U (Mt) 
[37, 53, 54, 63, 
132, 139, 182-
186] 
DnaG DNA primase all bacteria 
Ab, Bs, Ec, Fn, Hi, 
Mg, Mp, Mt, Pa, 
Sa, Sn 
RNA primase DnaB, SSB, DNA 
1D0Q (Gs), 1DDE (Ec), 1EQN 
(Ec), 3B39 (Ec), 2R6A (Gs), 
1Z8S (Gs), 2HAJ (Ec), 1T3W 
(Ec), 2AU3 (Aa) 
[37, 39, 50, 54, 
78, 137, 139, 140, 
187-189] 
DNA Pol III core       
DnaE 
 subunit, 
polymerase 
activity 
all bacteria 
Ab, Bs, Ec, Fn, Hi, 
Mg, Mp, Mt, Pa, 
Sa, Sn 
DNA polymerase ,  	 ,  , DNA 2HNH (Ec), 2HPI (Ta), 3E0D 
(Ta) 
[26, 164, 190-
194] 
DnaQ 
 subunit, 
proofreading 
activity 
/	/
-
proteobacteria 
Ab, Ec, Fn, Hi, Pa exonuclease ,  , DNA 1J53 (Ec), 2IDO (Ec) [192, 195-197] 
HolE  subunit enterobacteria D   2AXD (Ec), 2AE9 (Ec) [198-200] 
PolC polymerase 
activity 
firmicutes, 
tenericutes 
Bs, Mg, Mp, Sa 
DNA 
polymerase/ 
exonuclease 
	, , DNA 3F2B (Gk), 2P1J (Tm) [27, 28, 65, 75, 
163, 190] 
DNA Pol III clamp loader 
complex 
      
DnaX  and 
 
subunits 
all bacteria 
Ab, Bs, Ec, Fn, Hi, 
Mg, Mp, Mt, Pa, 
Sa, Sn 
ATPase , , ’, 
, , DnaB 2AYA (Ec), 3GLI (Ec), 1NJ5 
(Ec), 1XXH (Ec) 
[76, 201-204] 
HolA  subunit all bacteria Ab, Bs, Ec, Fn, Hi, 
Mp, Pa 
 , ’, 
, 	 3GLI (Ec), 1XXH (Ec), 1JQL 
(Ec) 
[76, 203, 205] 
HolB ’ subunit all bacteria Ab, Bs, Ec, Fn, Hi, 
Mg, Mp, Pa, Sa, Sn 
ATPase , , 
 3GLI (Ec), 1XXH (Ec) [76, 203] 
HolC  subunit /	/
-
proteobacteria 
Hi  , SSB 1EM8 (Ec) [78, 83, 206] 
HolD  subunit 
-proteobacteria D  , / 
 1EM8 (Ec) [76, 84, 206] 
Other replication proteins       
DnaN 
	 sliding 
clamp 
all bacteria 
Ab, Bs, Ec, Fn, Hi, 
Mg, Pa, Sa 
 
, , Hda, UmuC, 
UmuD, DinB1, MutS, 
MutL, DNA ligase, PolA, 
PolB, DNA 
2POL (Ec), 1JQL (Ec), 2AVT 
(Sp) 
[26, 45, 172, 191, 
192, 205, 207-
212] 
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(Table 1) Contd….. 
Protein Function 
Phylogenetic 
distribution 
Essentiality* 
Enzymatic 
activity
†
 
Interaction partners Structures
‡
 (organism)*
 
References 
SSB 
ssDNA 
binding 
all bacteria 
Ab, Bs, Ec, Fn, Hi, 
Mg, Mp, Pa, Sa, Sn 
 
DnaG, , RecQ, TopB, 
UmuC, RecJ, PriA, 
RecO, exonuclease I, 
GroEL, DNA 
1EQQ (Ec), 1Z9F (Tm), 2VW9 
(Hp), 1SE8 (Dr), 1UE1 (Mt), 
2FXQ (Ta) 
[46, 78, 79, 81-
83, 167, 213-225] 
PolA DNA 
polymerase I 
all bacteria Ab, Bs, Ec, Fn, Hi, 
Mg, Mp, Mt, Sa 
DNA 
polymerase/ 
exonuclease 
	, DNA 1DPI (Ec), 1KLN (Ec), 1KFS 
(Ec), 3BDP (Gs), 3KTQ (Ta) 
[190, 210, 226-
230] 
LigA DNA ligase all bacteria 
Ab, Bs, Ec, Fn, Hi, 
Mg, Mp, Mt, Pa, 
Sa, Sn 
DNA ligase 	, DNA 
2OWO (Ec), 1DGS (Tf), 1B04 
(Gs), 1TA8 (Ef), 3JSL (Sa), 
1ZAU (Mt) 
[210, 231-235] 
DNA 
gyrase 
DNA 
supercoiling 
all bacteria 
Ab, Bs, Ec, Fn, Hi, 
Mg, Mp, Mt, Pa, 
Sa, Sn 
topoisomerase 
ATPase 
GyrI, CcdB, DNA 2WL2 (Ec), 2XCQ (Sa), 2XCS 
(Sa), 2XCT (Sa) 
[103, 106] 
Tus terminator enterobacteria D  DNA 2EWJ (Ec) [43] 
RTP terminator some bacillales D  DNA 2EFW (Bs), 1BM9 (Bs),  
1F4K (Bs) 
[44, 236, 237] 
* Organism designations: Aa, Aquifex aeolicus; Ab, Acinetobacter baylyi; Bs, Bacillus subtilis; Dr, Deinococcus radiodurans; Ec, Escherichia coli; Ef, Enterococcus faecalis; Fn, 
Francisella novicida; Gk, Geobacillus kaustophilus; Gs, Geobacillus stearothermophilus; Hi, Haemophilus influenzae; Hp, Helicobacter pylori; Mt, Mycobacterium tuberculosis; Mg, 
Mycoplasma genitalium; Mp, Mycoplasma pulmonis; Pa, Pseudomonas aeruginosa; Sa, Staphylococcus aureus; Sm, Shewanella amazonensis; Sn, Streptococcus pneumoniae; Sp, 
Streptococcus pyogenes; St, Salmonella typhimurium; Ta, Thermus aquaticus; Tf, Thermus filiformis; Tm, Thermatoga maritima; Vc, Vibrio cholerae; D, dispensable; gene not found 
to be essential in any organism. 
† ,  no activity or no structure available 
‡ Codes shown are Protein Data Bank accession number 
 
loaded primer to begin synthesizing a new fragment. The 
RNA primers between fragments are removed by ribo-
nuclease HI and/or DNA polymerase I and replaced with 
DNA by the latter enzyme. Finally the DNA fragments are 
joined by DNA ligase to create a continuous lagging DNA 
strand. Throughout DNA synthesis, available template 
strands are coated by tetramers of the single-stranded DNA-
binding protein, SSB, which maintains contact with the 
replisome through interactions with primase and the  
subunit of the clamp loader. Despite the complexity of this 
process, DNA synthesis occurs with remarkable fidelity and 
at an astonishing rate, close to 1000 nt per second [40]. The 
bidirectionality of chromosome synthesis means that 
replication of the 4.6 Mb E. coli chromosome is completed 
in about 40 min. Coordinated leading and lagging strand 
synthesis requires that the replisome be highly dynamic, with 
components frequently being switched from one part of the 
template to another. This is made possible through a 
complex series of protein-protein interactions, some of 
which are only transient, that coordinate the various 
enzymatic modules within the replisome assembly. 
 Three-dimensional structures have now been determined 
for practically all the functional modules within the bacterial 
replisome, using proteins from E. coli and/or other orga-
nisms (Table 1). The network of protein-protein interactions 
has been largely determined. Inclusive of initiation com-
plexes, replisome components, SSB, DNA polymerase I and 
DNA ligase, replication of the bacterial chromosome at the 
very least requires nine distinct enzymatic activities and ten 
different protein-protein contacts to be made [32]. These 
numbers are even greater when essential, but non-universal, 
components (e.g. helicase loaders) are included. Each of 
these activities/interactions represents a potential target site  
 
for interference by antibiotic compounds. Despite this, very 
few inhibitors specific for bacterial DNA replication com-
ponents are available and the replication machinery remains 
an underexploited target for antibacterial chemotherapy. It is 
important, however, to consider our knowledge of DNA 
replication in the context of all bacteria, not just model 
organisms, if we are to choose DNA replication proteins as 
targets for drug discovery or rational drug design. 
CONSERVATION OF DNA REPLICATION 
COMPONENTS IN BACTERIA 
 With the abundance of bacterial genome sequence data 
now available, the sequence conservation and phylogenetic 
distribution of DNA replication proteins is becoming clear 
(Table 1). There is a basic replication module that is present 
in all bacteria and probably arose early in evolutionary 
history: the DnaA replication initiator, DnaB helicase (called 
DnaC in firmicutes like Bacillus spp.), DnaG primase, Pol III 
 (plus an additional, related PolC in some organisms), 	2,  
(part of PolC when PolC is present), 3,  and ’, SSB, DNA 
polymerase I and DNA ligase. This set of proteins consti-
tutes all of the components necessary to carry out and 
coordinate leading and lagging strand synthesis on a double-
stranded DNA template [26, 27]. Other modules are res-
tricted to particular phylogenetic groups and are likely 
therefore to have evolved more recently, presumably helping 
to regulate replication events. Some attributes, such as the 
fusion of ribonuclease HI to the  subunit of Pol III core [21, 
41], have a very restricted distribution (in this case to the 
family Moraxellacae). Certain other properties, such as the 
presence of replication termination systems in the 
Enterobacteriacae (Tus-Ter [42, 43]) and firmicutes (RTP-  
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Fig. (1). Architecture and conservation of bacterial replisomes. (A) Bidirectional replication of a circular bacterial chromosome initiates 
at oriC and terminates opposite. Green circles denote replisomes at replication forks. (B) Model for leading and lagging strand synthesis at a 
replication fork in E. coli. (C) Overlaid ribbon diagrams of the AAA+ domains of DnaA (PDB: 2HCB, blue), DnaC (PDB: 3ECC, green), 
DnaI (PDB: 2W58, pink) and Hda (PDB: 3BOS, cyan). The position of the ATP analog AMP-PCP (colored by atom type: C, yellow; N, 
blue; O, red; P, orange) and a Mg2+ ion (gray sphere) within the DnaA structure is shown. (D) Overlaid ribbon diagrams of the AAA+-like 
domains of the clamp loader subunits  (blue),  (magenta), and ’ (green). Coordinates were derived from PDB: 3GLI. The positions of 
ADP (colored by atom type, as above for ATP), the phosphate transition state analog BeF3 (Be, magenta; F, cyan) and a Mg
2+ ion (gray 
sphere) within the  subunit are shown. (E) Phylogenetic tree based on the sequences of DnaC/DnaI helicase loader proteins. The tree was 
constructed using the neighborhood-joining tree method in Geneious (Biomatters, Auckland, New Zealand), using the Jukes-Cantor genetic 
distance model and employing the bootstrap method with 100,000 replicates. The sequence of E. coli DnaA was included as an outgroup. 
Colored boxes indicate helicase loader families (enterobacteria DnaC-type, cyan; Aquificae DnaC-type, pink; firmicute DnaI-type, green). 
(F) Ribbon diagrams showing filaments of Aquifex aeolicus DnaC (PDB: 3ECC) formed by P61 crystal packing [49]. (G) Model for 
polymerase handover during lagging strand synthesis in Bacillus subtilis [27]. Panels (C), (D) and (F) were created using PyMOL [169]. 
 
Escherichia coli
Klebsiella pneumoniae
DnaA
Salmonella enterica
Persephonella marina
Aquifex aeolicus
Hydrogenobacter thermophilus
Clostridium botulinum
Streptococcus pyogenes
Bacillus subtilis
Staphylococcus aureus
0.2
DnaC
DnaC
DnaI
E
i. primer extension
helicase
primase
τ δδ'
SSB
Okazaki 
fragment
leading strand
lagging strand
5’
3’
5’
3’
PolC
PolC
DnaE
3
ii. elongation
5’
3’
5’
3’helicase
primase
τ δδ'
SSB
Okazaki 
fragment
leading strand
lagging strand
PolC
PolC
DnaE
3
C D
F
G
DnaB helicase
DnaG primase
Pol III
α
α
α β
β β
τ
τ
τ δ
δ'
SSB
Okazaki fragment
Pol I
DNA ligase
leading strand
lagging strand
fork progression
fork progression
A B
5’
3’
5’
3’RNA 
primer
oriC
Ter
ε
ε
ε
Bacterial DNA Replication as a Drug Target Current Drug Targets, 2012, Vol. 13, No. 3     357 
Ter [44]), are not essential for cell growth and are therefore 
of limited interest with respect to drug discovery. Only those 
components that are essential in those organisms that have 
them are discussed further.  
 In general the sequences of DNA replication proteins are 
moderately conserved among all bacteria. The genetically 
distant E. coli and B. subtilis, for example, share 11–49% 
sequence identity with respect to the proteins comprising the 
basic replication module. Overall the sequences of these 
proteins are less conserved than those of proteins involved in 
other informational processes such as RNA transcription and 
protein translation, but more conserved than proteins that 
function in metabolic pathways and other non-informational 
processes such as cell division [21]. Within the replication 
proteins, sequence motifs that encompass enzymatic sites are 
far more conserved than regions that mediate protein-protein 
interactions. Similarly, whole proteins that contain enzy-
matic active sites tend to be more conserved than those that 
only mediate protein-protein interactions. Notable exceptions 
to this are the highly conserved protein-protein interaction 
systems present on the 	-sliding clamp and SSB [21, 45, 46].  
 Several DNA replication proteins are paralogs of each 
other or share structurally related domains. Many belong to 
the AAA+ family of ATPases, which harness the energy 
liberated by ATP hydrolysis to perform mechanical func-
tions [47]. Within particular replication sub-complexes the 
AAA+ proteins are clearly related to each other. The initiator 
protein DnaA, for example, is closely related to the Hda 
initiation regulator and (when they are present) the helicase 
loaders DnaC and DnaI (Fig. 1C) [48, 49]. Similarly, the ,  
and ’ subunits of the clamp loader complex [47], while not 
all enzymatically active as ATPases, share significant 
sequence homology and have similar overall structures (Fig. 
1D). These similarities suggest that the members of each 
sub-complex often share a common ancestor; they presume-
ably arose through ancient gene duplication events, even-
tually diverging to take on distinctive roles in the replication 
process. 
 Structural homology is also seen among individual 
domains of some replication proteins. The N-terminal 
domain of the replicative helicase and the C-terminal domain 
of DNA primase, which interact to facilitate RNA primer 
synthesis, share a common fold despite negligible sequence 
similarity [39, 50, 51]. To date this fold has only been 
observed in these two proteins. Interestingly, weak sequence 
homology has recently been revealed for domains of two 
other replication proteins; the DnaB and DnaD replication 
initiator accessory proteins found in firmicutes (Table 1). 
Using Hidden Markov Model-based homology searches, 
Marston and colleagues were able to recognise two distinct 
homologous domains, DDBH1 and DDBH2, within these 
proteins [52]. DnaD has a DDBH1-DDBH2 domain structure 
while DnaB includes two DDBH2 domains and is arranged 
DDBH1-(DDBH2)2. Despite their extreme sequence diver-
gence, these domains share common attributes within the 
two proteins: the DDBH1 domains facilitate subunit tetra-
merization while the DDBH2 domains bind to DNA (double-
stranded DNA for DnaD and the C-terminal domain of 
DnaB; single-stranded DNA for the first DDBH2 domain of 
DnaB) and consequently facilitate protein oligomerization. 
Loading of the Replicative Helicase at oriC 
 The process of loading the replicative helicase at the 
origin has primarily been studied in two model organisms, 
the Gram-negative enterobacterium E. coli and the Gram-
positive firmicute B. subtilis. In both, the helicase associates 
with DnaA during loading. In E. coli, DnaA-dependent 
recruitment of DnaB at oriC requires the helicase to be in a 
complex ([DnaB6][DnaC]6) with its loader protein DnaC 
[53]. DnaC suppresses the ATPase activity of DnaB and 
remains bound throughout the loading process. Once loaded, 
primase associates with the helicase, triggering the release of 
DnaC to enable strand separation by the helicase to 
commence [54]. Loading of the replicative helicase (called 
DnaC) in B. subtilis follows a similar mechanism except that 
the helicase loader is called DnaI and the two additional 
proteins described above, DnaB and DnaD, are also required 
[55]. Smits and colleagues have recently delineated the order 
of protein associations at oriC that precede helicase loading 
in this organism [55]. DnaA binds first to oriC. The DNA 
remodeling protein DnaD is then recruited, either through 
interaction with DnaA or through direct interaction with non-
B-form DNA within the DnaA-coated oriC. Membrane-
associated DnaB molecules are then recruited, probably 
through direct interaction with DnaD. Finally, two DnaC 
helicase-DnaI helicase loader complexes associate with the 
origin, at which point the two helicase hexamers are loaded 
onto the DNA. The E. coli DnaC and B. subtilis DnaI loader 
proteins share significant sequence homology, suggesting 
that this final step might be somewhat conserved between 
the two organisms. Interestingly however, relatives of these 
loader proteins can only be found in a few select groups of 
organisms outside of the enterobacteria and firmicutes.  
 Members of the Aquificae, a small group of hyper-
thermophilic Gram-negative rods that includes the model 
organism Aquifex aeolicus [56], maintain a helicase loader 
known as DnaC that is a homolog of E. coli DnaC and B. 
subtilis DnaI [49]. As with E. coli, no relatives of B. subtilis 
DnaB or DnaD are present in these organisms. For this 
reason, the Aquificae DnaC proteins have been considered 
functionally equivalent to E. coli DnaC. Phylogenetic 
sequence analysis demonstrates, however, that Aquificae 
DnaC proteins are only distantly related to the other DnaC/I 
helicase loaders (Fig. 1E). This suggests that Aquificae 
DnaC proteins represent their own distinct family of helicase 
loaders and that they might have unique characteristics 
relative to members of the other two families.  
 Collectively, the DnaC/I-type helicase loaders are two-
domain proteins, with helicase binding being mediated 
through the N-terminal domain while ATPase activity and 
DNA binding occurs within the C-terminal AAA+ domain. 
Crystal structures of the C-terminal domains of A. aeolicus 
DnaC [49] and Geobacillus kaustophilus DnaI [57] reveal 
very similar overall structures (Fig. 1C). Sequence homo-
logy within this region suggests that the C-terminal domain 
of E. coli DnaC is probably also similar to the equivalent A. 
aeolicus and G. kaustophilus domains. The A. aeolicus 
domain was seen to form helical filaments in the crystalline 
state (Fig. 1F), reminiscent of filaments previously observed 
for ATP-bound DnaA from E. coli [49]. This helical 
arrangement is thought to represent a structure important for  
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helicase loading in vivo [49]. The fact that the C-terminal 
domains of helicase loaders are well conserved across the 
three families suggests that E. coli DnaC and B. subtilis DnaI 
probably also adopt helical arrangements during helicase 
loading.  
 The solution structure of the N-terminal domain of B. 
subtilis DnaI determined by NMR, which revealed a novel 
zinc-binding fold, provides the only structural definition of a 
helicase loader N-terminal domain [58]. The sequences of 
the N-terminal domains are conserved within each of the 
three helicase loader families; however these domains in E. 
coli and A. aeolicus DnaCs are clearly unrelated to that of B. 
subtilis DnaI. For both E. coli DnaC and B. subtilis DnaI, it 
is this N-terminal domain that facilitates binding to the 
helicase [53, 59]. Further work is required to determine if the 
structural basis of the helicase-helicase loader interactions is 
in any way conserved among the three helicase loader 
families. 
 The fact that DnaC/I-type helicase loaders are not 
conserved among all bacteria implies that organisms outside 
of the enterobacteria, firmicutes and Aquificae must either 
not require specialized helicase loader proteins or utilise 
proteins that are unrelated to DnaC/I for this function [21]. 
In support of the former scenario, Soni and colleagues have 
shown that the helicase from Helicobacter pylori, an 
organism that lacks an identifiable helicase loader, can be 
used to complement a temperature-sensitive dnaC mutant of 
E. coli [60]. This implies that the H. pylori helicase can be 
loaded onto the E. coli oriC using the E. coli machinery in 
the absence of a functional DnaC. One possibility is that 
DnaA could itself be sufficient for loading of the replicative 
helicase at oriC in organisms that lack helicase loaders. 
Indeed the helicases from two such organisms, Pseudomonas 
putida and P. aeruginosa can be loaded onto oriV of the 
RK2 plasmid in vitro using only DnaA [61]. In the same 
system, the E. coli helicase required DnaC to be present for 
loading onto oriV [61]. Another possibility is that organisms 
without DnaC/I might utilise replication restart complexes 
analogous to the PriA/PriB/DnaT system found in E. coli 
[62] to load the helicase at both origin and non-origin 
sequences. In fact in B. subtilis, the DnaB and DnaD proteins 
are required for loading the helicase both during initiation of 
DNA replication and for replication restart [63]. Interest-
ingly, homologs of B. subtilis DnaB are maintained within 
members of the tenericutes, which lack homologs of DnaD 
and DnaI (Table 1). In this case it is tempting to speculate 
that DnaB might assist other, as yet unidentified, helicase 
loaders in loading the helicase at oriC. 
 While helicase loaders are not found in all bacteria, they 
form an essential part of the DNA replication machinery in 
those organisms that have them (Table 1). Importantly, this 
includes several important human pathogens, such as E. coli, 
Salmonella typhimurium, Bacillus anthracis, Listeria 
monocytogenes, Clostridium botulinum, Staphylococcus 
aureus and Streptococcus pyogenes. For these organisms, 
helicase loaders might represent useful antibacterial drug 
targets. One could imagine, however, that relatively simple 
modifications to other helicase loading pathways (such as 
those involved in replication restart) might allow bacteria to 
survive should their DnaC/DnaI pathways be inhibited. 
Ultimately this may limit the usefulness of helicase loader 
inhibitors as antibiotics. 
DnaE1 versus PolC + DnaE3 Mechanisms 
 The majority of bacterial genomes sequenced to date 
contain a single type of replicative polymerase, the Pol III  
subunit, known under the polymerase classification scheme 
developed by Zhao and colleagues as DnaE1 [64]. It has 
long been known, however, that the Gram-positive B. 
subtilis uses two related, but distinct, replicase types known 
as PolC and DnaE3 [27, 64]. DnaE3 is homologous to 
DnaE1 and has a similar domain organization, while PolC is 
more distantly related to DnaE1, contains an additional -
related proofreading domain, and has a dissimilar arrange-
ment of functional domains [64]. Both PolC and DnaE3 are 
required for DNA replication in B. subtilis [65]. Based on the 
observation that DnaE3 deprivation immediately halts lag-
ging strand synthesis, while allowing leading strand 
synthesis to continue, it was originally hypothesized that 
PolC and DnaE3, respectively, constitute separate leading 
and lagging strand replicases [65], akin to the eukaryotic 
polymerases Pol  and Pol  [66]. Recently however, 
reconstitution of a functional B. subtilis replisome in vitro 
has shown that this is not the case [27]. 
 After identifying 13 proteins likely to comprise the 
replisome of B. subtilis (polymerases PolC and DnaE3, SSB, 
PriA, DnaG primase, DnaC helicase, DnaB, DnaD, and DnaI 
helicase loaders, the 	 clamp, and the clamp loader subunits 
, , and ’), Sanders and colleagues were able to purify each 
of these components and use them to carry out coordinated 
leading and lagging strand synthesis on a synthetic 
minicircle DNA template [27]. All 13 proteins were found to 
be required for lagging strand synthesis while DnaE3 and 
primase could be omitted for leading strand synthesis. It was 
found that both PolC and DnaE3 could extend DNA primers, 
but only DnaE3 could extend RNA primers like those laid 
down by primase. Inclusion of both PolC and DnaE3 had a 
strong synergistic effect on the rate of lagging strand 
synthesis. These observations are consistent with a model in 
which DnaE3 does not act as a dedicated lagging-strand 
polymerase, but rather acts to extend the RNA primers laid 
down by primase with a short stretch of DNA so that PolC 
can continue DNA synthesis (Fig 1G). The role of DnaE3 is 
thus analogous to that of the eukaryotic Pol , which extends 
RNA primers with DNA before handing them over to the 
lagging strand Pol   [27]. As PolC/DnaE3 are present in all 
firmicutes and tenericutes, this model probably applies to all 
organisms within these groups.  
Clamp Loader Subunits of DNA Polymerase III 
 At the heart of the Pol III holoenzyme (minimally 
[]3[3’][	2]2) is the heteropentameric clamp loader 
complex (3’). As its name suggests, this complex func-
tions to load 	-sliding clamps onto DNA primer-templates, 
bestowing leading- and lagging-strand processivity on the 
replicase [67]. Each of the three  subunits of the clamp 
loader also binds to the  subunit of a polymerase core, thus 
tethering three polymerases together to coordinate synthesis 
of the two strands [36]. In E. coli the dnaX gene encoding 
the  subunit includes sequence elements that induce a  
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ribosomal frameshift with approximately 50% efficiency 
[68-72]. This frameshift gives rise to a truncated form of , 
known as 
, comprising the N-terminal three domains out of 
five in the full-length  protein; 
 can replace  to form 
complexes that maintain clamp loading activity, but since it 
is the C-terminus of  that contacts , 
 cannot multimerize  
subunits to form a functional replicase. It has long been 
thought that the clamp loader complex in E. coli contains 
two  subunits and one 
, thus yielding a Pol III HE with two 
polymerase cores ([]2[2
’][	2]2). Recently however, 
the Leake and Sherratt groups have quantified each of the 
Pol III HE subunits at replication forks in living E. coli cells 
[36], presenting strong evidence that in vivo, replicases 
contain three  subunits and three  cores. The authors 
instead propose that clamp loader complexes containing 
 
subunits could function in other processes that require 
loading of 	-sliding clamps, such as in DNA repair [36]. The 
programmed ribosomal frameshift encoded within the E. coli 
dnaX gene is also conserved in the related organism 
Salmonella typhimurium [73]; in fact similar frameshift 
sequences are found within dnaX genes among all the 
enterobacteria. The dnaX gene of the hyperthermophilic 
Gram-negative organism Thermus thermophilus also 
produces both  and 
 products [74]. In this case 
 is 
produced by transcriptional slippage rather than a ribosomal 
frameshift. Most other bacteria, however, do not maintain 
frameshift signatures within their dnaX genes and may not, 
therefore, produce 
 subunits. Indeed the dnaX genes from B. 
subtilis, S. aureus, S. pyogenes, P. aeruginosa and A. 
aeolicus produce only full-length  products when expressed 
in recombinant E. coli systems [27-31, 75]. It appears likely 
that all bacteria maintain three  subunits within clamp 
loader complexes at replication forks and thus utilise trimeric 
polymerases to replicate their chromosomes. 
 In addition to ,  and ’ subunits, the clamp loader 
complexes of 
-proteobacteria include a heterodimeric sub-
complex made up of the  and  subunits (Table 1). This is 
tethered to the more universal clamp loader assembly (3’) 
through an interaction between the N-terminus of  and 
domain III from all three of the  subunits [76, 77]. The  
subunit interacts with the C-terminus of SSB, providing a 
mechanism for the handover of primed template DNA from 
primase to Pol III HE during lagging strand synthesis [78-
82]. Recently, the link between SSB and Pol III afforded by 
the  heterodimer has been shown to be crucial for strand 
displacement activity of Pol III HE [83]. It has also been 
demonstrated that the interaction of  with  significantly 
stimulates clamp-loading activity in E. coli and P. 
aeruginosa [30, 76, 77, 84]. Interestingly, while only one  
heterodimer can associate with each clamp loader complex, 
there are on average four  heterodimers at each replication 
fork in live E. coli cells, compared with one 3’ complex 
[36]. This suggests that additional  heterodimers associate 
with SSB at replication forks, awaiting handover to Pol III 
HE. 
 The gene encoding , holC, is dispensable in most 
organisms (Table 1) [14]) and can be disrupted in E. coli, 
although such disruptions show some growth defects [85]. 
The holD gene, which encodes  is dispensable in E. coli 
[85] but essential in both Acinetobacter baylyi [86] and P. 
aeruginosa [87]. The  proteins in these latter organisms are 
much longer than their E. coli counterpart and might 
therefore carry additional functions that are essential for 
survival [21, 84]. That the genes encoding  and/or  can be 
disrupted in E. coli and other bacteria suggests that their role 
in DNA replication is probably regulatory rather than being 
part of some fundamental mechanism. Interestingly, genes 
encoding  appear to be distributed across more of the 
bacteria (, 	 and 
-proteobacteria) than genes encoding  
(
-proteobacteria only; see Table 1). The  proteins have 
highly divergent sequences [21]; thus it is possible that the  
homologs in 	 and 
-proteobacteria have simply diverged 
beyond the detection limit of sequence similarity searches, 
including sensitive Hidden Markov Model-based methods 
[88, 89]. If there is a genuine discrepancy in the phylogenetic 
distribution of  and  subunits, however, this suggests that 
 may have evolved to interact directly with  and/or have 
extra functions outside of clamp loader complexes. 
Gene Duplications 
 Genome sequencing has revealed that many bacteria 
contain genes coding for multiple versions of certain replica-
tion proteins. Many of these proteins are potential drug 
targets and are discussed in detail in the next section. The  
subunit of Pol III, which provides the major DNA poly-
merase activity of the replisome, exists in at least four 
variants termed DnaE1, DnaE2, DnaE3 and PolC [64]. The 
first three variants have a similar sequential arrangement of 
PHP, polymerase and OB-fold domains within their primary 
sequences, yet can be classified into three different groups 
using sequence analysis. PolC proteins have regions homo-
logous to the domains found in DnaE-type polymerases, as 
well as an additional proofreading exonuclease domain. The 
arrangement of domains is different however, appearing in 
the primary sequence in the order OB-fold, PHP domain, 
exonuclease and finally the polymerase domain. As dis-
cussed above, all bacteria outside of the firmicutes and 
tenericutes have DnaE1, while organisms within these 
groups have both PolC and DnaE3. In contrast, DnaE2 does 
not conform to phylogenetic boundaries and can co-exist 
with DnaE1 or PolC and DnaE3. The error-prone DnaE2 
variant forms part of a LexA-regulated adaptive mutagenesis 
cassette, which appears to have originated in the actinobac-
teria but has since disseminated throughout other bacterial 
groups through lateral gene transfer [90]. DnaE2 variants are 
found in the important human pathogens Mycobacterium 
tuberculosis and P. aeruginosa and are likely to play a role 
in the development of antibiotic resistance in these orga-
nisms [91, 92]. 
 Other duplications of DNA replication proteins have 
more mysterious functions. The genomes of many Bacillus 
spp. contain a second copy of the dnaN gene, dnaN-2, cod-
ing for a 	-sliding clamp (DnaN-2) that shares approxi-
mately 40% sequence homology with its canonical-type 	-
sliding clamp (DnaN-1) [93]. In E. coli the 	-clamp is 
known to bind to the  subunit of Pol III as well as a host of 
DNA repair enzymes, thus playing a role in both replication 
and repair [45]. In B. anthracis, deletion of dnaN-2 produces 
a phenotype indistinguishable from wild-type, whereas 
deletion of dnaN-1 results in a mutator phenotype [93]. This, 
together with the fact that a dnaN-1/dnaN-2 double mutant 
could not be produced, suggests that DnaN-1 functions in 
both DNA replication and repair, while DnaN-2 can 
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participate in replication but is deficient in one or more DNA 
repair functions.  
 Duplications of genes encoding the  subunit of Pol III 
(dnaQ), DNA primase (dnaG) and SSB (ssb) can also be 
found within the genomes of a variety of diverse bacteria, 
not conforming to any obvious phylogenetic boundaries. 
While some attempts have been made to characterize the 
products of these duplicated genes, their biological roles 
remain unclear [94, 95]. Nevertheless, it is important to 
consider the existence of these gene duplications if the 
canonical versions of the proteins they encode are to be 
considered as drug targets, in particular whether any func-
tional redundancy may provide a selective advantage to their 
hosts when challenged by antibiotics. On the other hand, if 
two essential proteins with different functions are suffi-
ciently similar to be targeted by the same drug, then this 
would provide a substantial barrier to selection of resistant 
mutants in either. 
EXISTING INHIBITORS AND CURRENT SCREEN-
ING STRATEGIES 
 Of all the antibiotics in current clinical use, only two 
classes inhibit the process of DNA replication. The quino-
lone and aminocoumarin drugs inhibit the action of DNA 
gyrase, a type II toposiomerase that introduces negative 
supercoils in DNA ahead of replication forks to enable 
continued strand separation by the helicase during DNA 
replication [96]. Given that the replication machinery 
includes so many other proteins with functions essential for 
bacterial viability, it is likely that at least some are useful 
drug targets. The replisome is very much an under-explored 
target for drug development, however, and few attempts to 
discover specific inhibitors have been described. One of the 
major challenges in discovering DNA replication inhibitors 
has been the need for biochemical assays that can be used for 
high-throughput screening. Important advances have been 
made in this area recently and are likely to yield new inhibi-
tors in the near future. This section describes inhibitors that 
have been identified so far and the current strategies used for 
discovering new antagonists of replication activity. 
DNA Gyrase Inhibitors  
 Gyrase (a type IIA DNA topoisomerase) plays an 
essential role in DNA replication, actively underwinding the 
double-stranded template DNA ahead of the replication fork 
to obviate effects of positive supercoiling induced by the 
progressing replisome. It acts by cutting both DNA strands, 
passing double-stranded DNA through the gap, then religat-
ing the original ends [97]. It is a heterotetrameric enzyme 
comprised of two different subunits: GyrA, which binds 
DNA and carries out strand cleavage/ligation, and GyrB, 
which hydrolyses ATP to drive the supercoiling reaction. 
Gyrase is the cellular target of several different classes of 
bacteriocidal agents, including the highly-successful fluoro-
quinolone antibiotics, coumarins and cyclothialidines that 
are currently undergoing drug development, as well as a 
range of naturally-occurring bacterial toxins [22, 97]. Much 
of the current research on gyrase inhibitors focuses on 
modifying existing scaffolds to address issues with drug 
resistance, toxic side effects and poor cellular penetration, as 
well as to broaden the range of bacterial species that com-
pounds are active against [22, 97, 98]. Structure-aided design 
and virtual screening techniques have proven somewhat 
successful in delivering new classes of gyrase inhibitors, 
some of which show broad-spectrum antibacterial activity 
and reduced rates of resistance relative to exisiting drugs [99, 
100]. Most recently, there has been exciting progress with 
two novel classes of gyrase inhibitors that show great 
promise for development into new antibiotics in the near 
future. 
 The novel antibiotic simocyclinone D8 was originally 
identified in extracts from the antibiotic-producing bacterium 
Streptomyces antibioticus Tü 6040 [101]. This compound 
has a chlorinated aminocoumarin group linked to an angu-
cyclic polyketide moiety through a tetraene linker and a D-
olivose sugar (Fig. 2A). The presence of the aminocoumarin 
group suggested DNA gyrase to be the cellular target and 
simocyclinone D8 was shown to potently inhibit the E. coli 
enzyme in vitro [102]. Unlike the aminocoumarin antibiotics 
however, simocyclinone D8 was found not to inhibit the 
ATPase activity of the GyrB subunit, nor did it stimulate the 
formation of unproductive cleavage complexes within the 
GyrA subunit as seen with quinolone compounds, suggesting 
an entirely novel mode of inhibition [102]. Edwards and 
colleagues have recently determined the crystal structure of 
simocyclinone D8 in complex with the N-terminal domain of 
the GyrA subunit, revealing binding pockets for the amino-
coumarin and polyketide moieties close to, but distinct from 
a previously identified quinolone-binding site [103]. This 
represents a significant step in the development of simocyc-
linones into clinically useful antibiotics, as structure-based 
activity relationships can now be explored. In addition to this 
binding site within the GyrA subunit, biochemical studies 
have suggested the existence of a second low-affinity bind-
ing site within GyrB [104]. Further work is now required to 
explore the possibility of cooperative binding at the GyrA 
and GyrB sites. Interestingly, while simocyclinone D8 shows 
poor activity against Gram-negative laboratory bacteria and 
is thus being viewed as a potential treatment only for infec-
tions caused by Gram-positives, it has recently been found to 
have potent activity against a number of Gram-negatives 
isolated from clinical samples [105]. This observation is 
likely to assist in identifying parameters that can be opti-
mized to broaden the spectrum of activity of simocyclinones, 
and adds to the promise of these compounds becoming 
clinically useful antibiotics. 
 A very promising new antibiotic that acts on gyrase has 
been recently described by GlaxoSmithKline researchers 
[106]. GSK299423 (Fig. 2B) is a member of the novel bac-
terial topoisomerase inhibitors (NBTI) family of compounds, 
which has also been explored by Novoxel [107] and Johnson 
& Johnson [108, 109]. GSK299423 strongly inhibits the 
activity of S. aureus and E. coli gyrase in vitro (IC50 = 14–
100 nM), making it more than 2000 times more potent than 
the widely used drug ciprofloxacin (a fluoroquinolone) 
[106]. GSK299423 shows potent antibacterial activity 
against a range of Gram-positive and Gram-negative 
pathogens (MIC = 0.016–8 μg/mL), including strains that are 
resistant to fluoroquinolones. The crystal structure of the 
gyrase-DNA-GSK299423 complex has been determined 
using the S. aureus enzyme, revealing that the compound 
binds between the active sites of the two GyrA subunits, 
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away from known binding sites for quinolone-type inhibitors 
[106]. GSK299423 appears to inhibit the catalytic cycle of 
gyrase by stabilizing a pre-cleavage enzyme-DNA complex, 
an entirely novel mode of gyrase inhibition. Taken together, 
the potency of GSK299423, its broad-spectrum activity and 
its lack of cross-resistance with existing fluoroquinolones 
suggest the NBTIs represent exciting candidates for 
development into a much-needed new class of antibiotics 
with a novel mode of action. 
Inhibitors of DNA Polymerase Activity 
 DNA polymerases are the targets of several important 
anti-viral and anti-cancer drugs, yet few inhibitors exist for 
the equivalent bacterial enzymes [110]. To date, there are no 
known inhibitors that are specific for DnaE1-type poly-
merases (e.g. the  subunit of E. coli Pol III). Two classes of 
compounds are known to effectively inhibit the PolC-type 
polymerases found in the firmicutes and tenericutes: 6-
anilinouracils (6-AUs) and quinazolin-2-ylamino-quinazolin-
4-ols (BisQuinols). Members of a third class of compounds, 
the dichlorobenzylguanines, have been shown to inhibit the 
activities of DnaE1-, DnaE3- and PolC-type polymerases, 
although no analysis of their antimicrobial properties has 
been published since their syntheses were described six years 
ago [111].  
 The 6-anilinouracils are the oldest and most developed 
class of DNA polymerase inhibitors [112-114]. These 
compounds are competitive inhibitors of dGTP binding to 
PolC [115], forming a three-hydrogen-bond base pair with 
cytosine residues in the template DNA (Fig. 3A). Many 
variations have been made on the original 6-AU scaffold, 
producing several compounds that potently inhibit PolC 
activity and bacterial growth in vitro [115-119]. Historically 
however, 6-AUs have proven modest inhibitors of bacterial 
growth in animal infection models due to poor solubility and 
bioavailability [120]. Most compounds that have demons-
trated activity in vivo have been tested using intraperitoneal 
dosing, which largely circumvents the problems associated 
with poor sample solubility. Recently, Svenstrup and col-
leagues addressed this issue by varying 3-substituents on the 
6-AU scaffold with a view to improving aqueous solubility, 
and in doing so have produced two compounds (Fig. 3B) that 
show strong activity against S. aureus and Enterococcus 
faecalis using intravenous dosing in a mouse infection model 
[118]. It is hoped that this advance in understanding of the 
structure-activity relationships of 6-AUs will facilitate the 
development of clinically useful compounds.  
 Members of the second class of PolC inhibitors, the 
BisQuinols, were discovered recently using high-throughput 
fluorescence-based inhibition assays [121]. The methodo-
logy underlying these assays is described later in this section. 
It was predicted that BisQuinols might base pair with cyto-
sine residues in DNA templates and thus be competitive with 
dGTP substrates, as observed for the 6-AUs. Biochemical 
analysis revealed, however, that BisQuinols were uncom-
petitive with respect to nucleotide substrates, instead show-
ing competitive behaviour against template DNA. The 
mechanism of PolC inhibition by BisQuinols must therefore 
be different to that of 6-AU compounds and appears to be 
more analogous to that of non-nucleoside reverse transcript-
tase inhibitors used to treat HIV infections [121, 122]. 
Importantly, the initial series of BisQuinol compounds also 
showed significant inhibition of the eukaryotic Pol  and 
thus appears to show poor selectivity for bacterial DNA 
polymerases [121]. Nevertheless, one representative com-
pound (Fig. 3C) was found to be somewhat effective in 
rescuing mice from a lethal intraperitoneal S. aureus 
infection, thus demonstrating a degree of in vivo efficacy. A 
better understanding of the structure-activity relationships 
for this novel class of PolC inhibitors is now required to 
assess their potential for development into functional 
antibiotics. 
 A promising new strategy for the development of PolC 
inhibitors is to covalently link 6-anilinouracil derivatives to 
fluoroquinolones to create hybrid PolC-DNA gyrase inhibi-
tors. These hybrid compounds maintain dual anti-PolC and 
anti-DNA gyrase activity in vivo and have greater or equal 
potency against whole bacterial cells than their isolated 6-
AU or fluoroquinolone parent compounds [116, 123, 124]. 
In fact when testing one representative hybrid (Fig. 3D), 
Butler and colleagues observed that the fusion to fluro-
quinolone actually increased the anti-PolC activity of the 6-
OHO
Cl
OH
H
N
O
O
O
OOH3C
O
OH OH OH
OH
CH3
HOO
O
O
H3C
N
O
NHN
N
S
O
A
B
 
Fig. (2). Chemical structures of new inhibitors of DNA gyrase. (A) Simocyclinone D8 [101-105]. (B) GSK299423 [106]. 
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AU moiety [116]. Even more promisingly, in cases where 
each of the parent compounds was only weakly active in 
isolation, i.e. for drug-resistant organisms, the hybrid com-
pound was found to offer greater potency than an equimolar 
mixture of its parents. The hybrid compound was thus 
effective against a broader range of bacterial strains than 
either parent, an attribute also observed for oxazolidinone-
quinolone hybrid protein synthesis/DNA gyrase inhibitors 
[125, 126]. The use of hybrid inhibitors intuitively should 
provide greater protection against the development of drug 
resistance by target mutagenesis than traditional single-target 
inhibitors – this would require co-mutation of two loci in the 
bacterial population. This indeed appears to be the case for 
Butler’s hybrid compound, for which resistance in S. aureus 
was seen to develop far more slowly than resistance to either 
parent compound in a simple pure culture system [116].  
 Several bacterial replisomes have now been reconstituted 
and are functional in vitro [26-28, 30, 127]. For E. coli and 
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Fig. (3). DNA polymerase inhibitors. (A) Three-hydrogen-bond interaction between 6-anilinouracil compounds and a cytosine residue 
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B. subtilis, this includes all the machinery required for both 
leading and lagging strand synthesis [26, 27]. For other 
species, more minimal replisomes capable only of leading 
strand synthesis have been assembled [28, 30]. Recently, 
Dallmann and colleagues described a high-throughput assay 
to screen for inhibitors of reconstituted replicase activity, 
making use of an intercalating fluorescent dye to monitor 
conversion of single-stranded DNA substrates into a double-
stranded product [127]. This approach has a significant 
advantage over assays that focus on isolated replication 
components, in that inhibitors of any part of the replication 
machinery can be identified through a common endpoint. 
These workers also included specificity assays to test if 
compounds bind to DNA, or inhibit viral and eukaryotic 
DNA polymerases, RNA polymerase, an unrelated eukaryo-
tic ATPase or an unrelated control enzyme, 	-galactosidase. 
Using these assays, they screened a small library of 2000 
compounds and identified seven (Fig. 3E) that act as specific 
inhibitors of bacterial replisomes and kill bacterial cells by 
inhibiting DNA replication. This high-throughput assay 
approach thus provides an efficient means to generate lead 
compounds for further drug development, and could be 
applied equally well for screening natural product and 
commercially available libraries of drug-like compounds.  
Inhibitors of Primosome Functions 
 Outside of DNA gyrase and the replicative polymerases, 
another replication subcomplex to be targeted for drug dis-
covery has been the primosome, comprised of the DnaB/C 
helicase and DnaG primase (see Table 1). These proteins 
play critical roles in lagging strand synthesis and are essen-
tial for bacterial growth [40, 85, 128]. These proteins are 
targets for some naturally occurring DNA replication 
inhibitors. The dietary flavonoid myricetin (Fig. 4A), for 
instance, has antimicrobial activity and has been shown to 
potently inhibit the replicative helicase, but not primase 
[129]. The bacterial alarmone compound (p)ppGpp on the 
other hand, is now known to inhibit the activity of primase, 
thereby halting DNA replication as part of the stringent 
response [130, 131]. The existence of these natural, low 
molecular weight inhibitors lends hope that the primosome 
subcomplex might be a viable target for drug discovery. 
 The replicative helicase has two functional domains. The 
N-terminal domain recruits primase to the replication fork, 
while helicase activity stems from the C-terminal domain. 
The helicase domain belongs to the RecA-type family of 
ATPases [132], which includes the bacterial replication/ 
recombination/repair proteins RepA [133] and RecA [134], 
the transcription termination factor Rho [135] as well as the 
eukaryotic DNA repair proteins Rad51 and DMC1 [136]. On 
the other hand, primase has a central RNA polymerase 
domain that is not related to other RNA polymerases and has 
a uniquely-shaped active site [137]. This domain is flanked 
by an N-terminal zinc-binding domain, which binds to 
specific trinucleotide initiation sequences on the template 
DNA, and a C-terminal domain that binds to the helicase 
[138]. Primase interacts with the helicase to enable primer 
synthesis on the lagging strand in vivo [32]. This interaction 
stimulates the activity of both proteins in vitro [139] and 
varies in strength, ranging from a weak and transient 
complex as observed for the E. coli proteins [140] to a highly 
stable complex as for the G. stearothermophilus proteins 
[37]. 
 In recent years high-throughput biochemical assays have 
been developed to measure the activities of helicase and 
primase, as well as the mutually stimulatory effects of their 
interaction [141-143]. Application of these assays in drug 
discovery has been limited, however, and has produced only 
a few inhibitors [144-146]. The Förster resonance energy 
transfer (FRET) assay for DnaB helicase activity developed 
by Zhang and colleagues [141], for instance, has been used 
by researchers at Targanta Therapeutics to screen a library of 
230,000 commercially available compounds for inhibitors of 
P. aeruginosa DnaB [147]. The Pseudomonas DnaB helicase 
was used as it can be efficiently loaded onto substrate DNA 
molecules in the absence of a helicase loader protein, in 
contrast to the equivalent helicases from E. coli and B. 
subtilis [61, 148]. Their screen revealed a triaminotriazine 
compound that inhibited the helicase with IC50 = 5 μM (Fig. 
4B). Despite showing potent inhibition of the P. aeruginosa 
DnaB in vitro, neither the newly identified compound nor 
analogs prepared to explore effects on cytotoxicity were 
found to inhibit the growth of P. aeruginosa cells, despite 
the fact that a permeability barrier-deficient strain was used 
[147]. Some compounds were, however, moderately active 
in inhibiting the growth of S. aureus, S. pneumoniae and a 
hyper-susceptible strain of E. coli. Unfortunately, this series 
of compounds exhibited a range of undesirable properties, 
including cytotoxicity towards HeLa cells and loss of 
antimicrobial activity in the presence of serum, that 
ultimately deem them unsuitable as lead compounds for 
antibiotic development. To date this represents the only 
reported systematic attempt to identify specific inhibitors of 
replicative helicase function. 
 DNA primase has attracted slightly more attention as a 
drug target, although success has again been limited. To date 
all searches for inhibitors have utilized the scintillation 
proximity assay for primase activity developed by Zhang and 
colleagues [141]. The assay is based on the ability of 
primase to incorporate radioactive 3H-labeled NTP substrates 
into an RNA product, which is then captured using a biotin 
tag on the template DNA strand to which the RNA product 
remains hybridized. Researchers at Schering Plough used 
this assay to screen extracts of various plants for inhibitors of 
E. coli primase [144], unearthing two novel phenolic 
saccharides from Polygonum cusoidatum that produced IC50 
values < 5 μM (Fig. 4C). Unfortunately, these compounds 
appear to act by binding to the template DNA rather than to 
primase itself and are therefore not appropriate lead 
compounds [129, 144]. In another similar study conducted 
by Schering Plough researchers, a novel bicyclic macrolide 
compound, Sch 642305 (Fig. 4D), was isolated from the 
fungus Penicillium verrucosum and found to inhibit E. coli 
primase with an IC50 of 70 μM [146]. Promisingly, Sch 
642305 also inhibited the growth of the E. coli strain HS294 
(defective lipopolysaccharide layer and disrupted acrAB 
efflux pump) with an MIC of 40 μg/mL. As yet no attempts 
have been reported to establish the mode of Sch 642305 
inhibition. Presumably this is due to difficulty in obtaining 
sufficient material for biochemical analysis, although several 
synthetic approaches for production of Sch 642305 have now 
been described [149-151]. Before Sch 642305 can be 
considered as a lead compound, further work is required to 
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determine its mode of action, as well as its efficacy against 
other bacterial strains in both in vitro cell growth and in vivo 
animal infection models. 
 Making use of the high-resolution crystal structure of the 
RNA polymerase domain of E. coli primase [137], Agarwal 
and colleagues at Achillion Pharmaceuticals used virtual 
screening to identify three potentially ‘druggable’ sites 
within primase [145]. They selected 79 compounds predicted 
to bind at these sites, and using the scintillation proximity 
assay [152] identified four inhibitors with IC50 values of 7–
50 μM [145]. None of these compounds was active in 
inhibiting the growth of E. coli cells, however. The initial 
four compounds were used to deduce a three-dimensional 
pharmacophore, which was then used to search a database of 
commercially available compounds for other potential 
inhibitors. From this search, a further 34 chemically diverse 
compounds were selected for enzyme inhibition assays, 
revealing eight additional compounds that inhibited primase 
with IC50 values < 100 μM. Three of these also inhibited the 
growth of E. coli, with MIC values of 4–64 μg/mL (Fig. 4E). 
Analogs of these compounds were then studied with these 
assays, allowing structure-activity relationships to be 
deduced for each chemical series [145]. Further work is now 
required to assess the efficacy of these compounds against 
other bacterial strains for antibiotic development. 
Inhibitors of the Initiation of DNA Replication 
 A relatively new approach towards the discovery of DNA 
replication inhibitors is to target the initiation stage. In 
(almost) all bacteria, the first step in replicating the 
chromosome is the binding of multiple DnaA molecules at 
the origin, which ultimately leads to separation of the two 
template strands [153]. Since this step signifies commitment 
to a complete round of replication, the amount and activity 
of DnaA is tightly regulated within the cell. Insufficient 
DnaA leads to under-initiation, while excess leads to over-
initiation. Both disrupt cell growth. Currently, no 
antibacterial agents target the initiation process.  
 Fossum and colleagues have recently developed a robust 
cell-based assay to screen for inhibitors of DnaA activity 
[154]. The assay utilises an E. coli strain containing a novel 
dnaA allele that produces an over-active DnaA variant and 
confers a cold-sensitive phenotype. This strain grows well at 
N
N
N
NH
N
H
N
H
N
O
O2N
Cl
A
HO
HO
HO
O
O
O
OH
OH
OH
O
OH
OH
HO O
OH
OH
O
OH
OH
HO
HO OH
O
O
B
C
O
O
HHO
O
H
O
N
N
O
N
D
N
S
N
N
S
HN
N
N
N
N
N
O
OOH
HO
OH
OH
OH
E
 
Fig. (4). Chemical structures of inhibitors of primosome functions. (A) The DnaB helicase inhibitor, myricetin [129]. (B) A 
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the permissive temperature (42˚C), but grows poorly at 30˚C 
due to excessive initiation of DNA replication. Compounds 
that inhibit DnaA activity reduce the initiation rate and thus 
restore cell growth at 30˚C. This was demonstrated by 
expressing moderate levels of the DnaA N-terminal domain, 
a competitive inhibitor of full-length DnaA, within the cells. 
While a small-scale screen of microbial extracts failed to 
identify any inhibitors of DnaA activity, the simplicity of 
this assay would easily facilitate larger screens and could 
lead to the discovery of inhibitors in the future. 
 A second cell-based assay has been developed recently 
with the aim of discovering inhibitors of replication initiation 
in Vibrio spp. [155]. This group of bacteria includes the 
causative agent of cholera, common sources of food 
poisoning and pathogens of economically important marine 
animals. Unlike most bacteria, Vibrio spp. contain two 
chromosomes, only one of which is replicated in a DnaA-
dependent manner. Initiation of replication at the second 
chromosome relies on the activity of a second protein, RctB, 
that bears no sequence similarity to DnaA [156]. Yamaichi 
and colleagues established a cell-based screen for identifying 
inhibitors of V. cholerae RctB [155]. The assay uses an E. 
coli strain that carries an RctB-dependent plasmid expressing 
both RctB and a kanamycin-resistance marker. If RctB is 
inhibited by a compound the cells cannot replicate the 
plasmid and thus do not grow on kanamycin-containing 
media. Using this strain, the group screened a library of 
138,000 small molecules, identifying a potent inhibitor of 
RctB, vibrepin, that inhibited the growth of all tested Vibrio 
spp. but had no effect on the growth of wild-type E. coli 
cells. If RctB inhibitors such as vibrepin can be developed 
into functional antibiotics, they should only kill the 
infectious Vibrio spp. whilst not affecting the natural gut 
flora of a patient, offering a significant advantage over 
current treatment options. 
POTENTIAL OPPORTUNITIES FOR DRUG 
DISCOVERY 
Structure-Aided Design 
 Despite the fact that three-dimensional structures are 
known for most bacterial replication proteins, few attempts 
to design novel inhibitors using structure-aided drug design 
have been described. Structure-aided design involves in 
silico screening of small molecule libraries, seeking to 
identify compounds that dock into binding sites on the 
surface of the target protein [157]. Docked ligands are then 
expanded to maximize contacts with the protein, to optimise 
the affinity of the small molecule for the binding site. A 
major challenge is that X-ray crystal structures, the most 
common source of structural data for proteins, provide only a 
structural snapshot (i.e. a single conformation) that might not 
reflect aspects of flexibility important for the in vivo activity 
of the protein. Structure-aided design does have the advant-
age that structure-activity relationships can often be easily 
deduced and important parameters can be rationalized on the 
basis of the geometry of binding pockets. Historically how-
ever, compounds designed this way very often have prob-
lems with toxic side effects [158]. Nevertheless, a small 
number of drugs produced using computer-aided design have 
made it into clinical use [158, 159].  
 The most common design strategy is to target enzyme 
active sites within the protein structures [157]. The replica-
tion machinery includes DNA and RNA polymerase sites as 
well as several ATPases. Given the ubiquity of ATP trans-
actions in all living cells, these latter enzymes present a 
significant challenge for rational design of inhibitors with 
high specificity. Nonetheless, studies using bacteriophage 
replicases have shown that it is possible to develop inhibitors 
with specificity towards certain ATPase active sites over 
others [160]. Given that many of the ATPases in the 
bacterial replication machinery are related (Fig. 1B-C), it 
might be possible to develop compounds that inhibit multiple 
essential replication components, yet do not act on unrelated 
ATPases. The mode of ATP binding has been deduced for 
all of the replisome-associated AAA+ proteins and key resi-
dues comprising binding pockets have been identified [49, 
57, 76, 161, 162]. Replicative and non-replicative AAA+ 
proteins could now be compared to assess similarities and 
differences in binding sites that could be exploited to design 
compounds that specifically inhibit bacterial DNA 
replication. 
 The high-resolution crystal structure of G. kaustophilus 
PolC in complex with template DNA and dGTP substrate 
has provided the first detailed view of the active site of a 
bacterial chromosomal replicase [163]. Residues comprising 
the active site are highly conserved in the PolC subunits of 
other firmicutes, including those of several pathogens. The 
crystal structure of PolC will likely form an excellent model 
for structure-aided drug design, particularly if further 
structures can be solved for complexes with 6-anilinouracil-
type inhibitors. Unfortunately, due to poor sequence conser-
vation between PolC and DnaE1-type polymerases (e.g. the 
Pol III  subunit) and the low resolution of structural 
information for the ternary complex between DnaE1 and 
DNA [164], it is difficult at the moment to model the DnaE1 
active site. The specificity for 6-AUs towards PolC over 
DnaE1-type polymerases suggests that there are significant 
differences in architecture of active sites between the two 
types. Higher-resolution data are required for DnaE1-DNA-
substrate complexes if this form of polymerase is to be used 
in structure-aided design. 
 The replisome is a highly dynamic complex in which 
many proteins are tethered to each other by way of flexible 
linkers. Almost all of the extant structural data has involved 
truncation of proteins to individual domains or removal of 
flexible portions. Identifying constructs suitable for structure 
determination has proven one of the key challenges in the 
study of replication proteins. Now that crystallizable cons-
tructs are available, many are prime candidates for structure-
based fragment screening approaches [165]. This strategy 
involves determining many (often several hundred) high-
resolution structures of the protein of interest, after exposing 
crystals of it to mixtures of drug-like fragments. Fragments 
found to bind at adjacent sites on the protein surface are then 
linked, producing a tighter-binding compound that acts as a 
lead for drug development. Fragment-based screening uses 
smaller compound libraries compared to other high-
throughput screening approaches and has greater hit rates 
against difficult targets [165]. It is anticipated that if applied 
to replication proteins, fragment screening could yield novel 
inhibitors of enzymatic activities and protein-protein interac-
tions that are crucial for replication, and thus provide a 
366    Current Drug Targets, 2012, Vol. 13, No. 3 Robinson et al. 
starting point for the development of novel antibiotics that 
target the DNA replication machinery.  
Protein-Protein Interaction Hubs 
 The portions of replication proteins that form protein-
protein contacts are generally poorly conserved among 
bacterial genera. There are, however, two protein-protein 
interaction systems in bacterial replication that are extremely 
well conserved – those based around the 	-sliding clamp and 
SSB [21]. The -sliding clamp is known to bind (at least) to 
DNA polymerases I, II, III, IV and V, DNA ligase, Hda, 
MutS and MutL in E. coli, acting to recruit these proteins to 
their sites of action on double-stranded DNA during 
replication and repair processes [21, 45]. As far as is known, 
each of these proteins binds to the same hydrophobic groove 
on the -sliding clamp by way of a pentameric or hexameric 
peptide motif, often located at or close to the N- or C-
terminus [45]. The hydrophobic groove on the -sliding 
clamp and its binding motifs in other proteins are strongly 
conserved across bacterial species [21]. An analogous 
mechanism is also shared by the PCNA sliding clamp of 
archaea and eukaryotes, although the consensus sequence 
recognised by PCNA is different from that of the bacterial -
binding motifs. The strong conservation of this protein 
binding mechanism across bacteria, together with the 
essentiality of many of the interactions formed at this single 
site, makes the protein-binding groove of the -sliding clamp 
an attractive target for rational antibiotic design.  
 The O’Donnell group has recently developed a high-
throughput fluorescence polarization anisotropy assay for 
identifying inhibitors of -clamp-DNA polymerase interac-
tions [166]. The assay is based on the displacement of a 
fluorescent TAMN-labeled peptide, derived from the E. coli 
Pol III  subunit, from its binding site on the -clamp. From 
a library of >30,000 small molecules, 91 inhibitors were 
identified. These were then screened in a DNA replication 
assay, revealing 19 compounds that specifically inhibited the 
	-dependent activity of Pol III HE. A subset of these com-
pounds was also active in displacing a PolC-derived peptide 
from S. pyogenes 	, consistent with the high level of con-
servation of protein-binding-site residues in 	 subunits from 
diverse bacteria [21]. One compound, RU7 (Fig. 5A), was 
further capable of differential inhibition of binding of 
various polymerases to 	, inhibiting the 	-dependent acti-
vities of Pol III and Pol II, but not Pol IV [166]. Importantly, 
RU7 was found not to inhibit PCNA-dependent DNA syn-
thesis by a model eukaryotic polymerase, yeast Pol . The 
O’Donnell compounds seem to be useful leads that could 
eventually be developed into a new class of bacterial DNA 
replication inhibitors. 
 SSB also interacts with many DNA replication and repair 
proteins by way of a conserved peptide motif, recruiting 
them to their sites of action on single-stranded DNA [21, 
46]. These interactions are mediated by the final 6–9 
residues at the C-terminus of SSB [79], which in E. coli has 
the sequence -MDFDDDIPF. These residues are highly 
conserved across a wide range of bacterial species, indicating 
that this system is probably used universally by bacteria. A 
crystal structure of the terminal SSB peptide in complex with 
exonuclease I shows the final two residues of SSB bind 
within a hydrophobic pocket on the exonuclease I surface 
[167]. It is anticipated that its binding to other proteins 
occurs in a similar fashion. By employing a fluorescence 
polarization anisotropy assay similar to that developed for 
monitoring 	-clamp interactions [166], Keck and colleagues 
screened a library of >50,000 small molecules, identifying 
four (Fig. 5B) that disrupt the interaction between the SSB 
C-terminus and exonuclease I [168]. Of these, two contained 
groups analogous to the Phe residue at the C-terminus of 
SSB. Interestingly, these same two compounds inhibited 
SSB interactions with RecQ and PriA, each structurally 
unrelated to exonuclease I, demonstrating at least some 
similarity in the arrangement of SSB binding sites in these 
proteins. Given that the SSB protein interaction system is 
conserved in bacteria, but not present in eukaryotes, it may 
be possible to develop these compounds into selective 
inhibitors of bacterial DNA replication. 
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Fig. (5). Chemical structures of protein-protein interaction 
inhibitors. (A) RU7, an inhibitor of 	-sliding clamp interactions 
[166]. (B) Inhibitors of interactions mediated by the conserved C-
terminal peptide of SSB [168]. 
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 The -clamp and SSB interaction hubs are promising 
novel drug targets. If inhibitors of these interactions can be 
designed, they should be capable of simultaneously dis-
rupting several functions critical to the survival of a bacterial 
cell. Such inhibitors should also have broad-spectrum 
activity as these modules are highly conserved. Finally, and 
perhaps most crucially, the fact that numerous proteins 
interact at a single site on each of these hubs should help to 
preclude development of resistance to such inhibitors – 
development of resistance by target modification would 
require simultaneous mutation of many different essential 
sites. The accumulation of point mutations that decrease the 
affinity of inhibitory compounds for their target is a common 
route to antibiotic resistance. In the case of protein-protein 
interaction sites, any mutation occurring on one interacting 
partner needs compensatory mutation(s) on another to 
maintain the integrity of the (essential) interaction site. For 
this to occur in the -clamp and SSB protein-binding sites, it 
would necessitate the unlikely acquisition of simultaneous 
compensatory mutations in the binding sites of many or all 
of the numerous proteins that bind at these sites.  
PERSPECTIVES 
 The lack of antibiotics that target the bacterial DNA 
replication machinery is perhaps surprising given that it is 
one of the best characterized and understood of complex 
biological processes. Unlike many other essential processes, 
few useful inhibitors of replication proteins have been 
discovered within natural product extracts. One explanation 
might be that inhibiting bacterial replisomes is inherently 
difficult and that even Nature has struggled to develop small 
molecule inhibitors against them. Until recently, however, 
suitable assays to test for specific inhibition of the replica-
tion machinery have not been widely available, so useful 
replication inhibitors might simply have gone undiscovered. 
A series of assays has now been developed that allow for 
high-throughput screening for inhibitors. Together with an 
abundance of protein structural data and a solid understand-
ing of the protein-protein interactions present within active 
replisomes, it is hoped that selective inhibitors can be deve-
loped in the near future. We must however, learn from 
lessons of the past and choose targets that minimize oppor-
tunities for the development of drug resistance. One way that 
this can be achieved is by incorporating genome sequence 
data into the target selection process, to ensure that only 
highly conserved components of the replication machinery 
are marked for drug development. With this in mind, the 
enzymatic sites found in the replicative DNA polymerases, 
primase, helicase and various AAA+ proteins, as well as the 
highly conserved protein interaction hubs formed around the 
	-sliding clamp and SSB are likely to have the most 
potential as targets for drug discovery and rational design. 
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